Sanofi Logo
CAD Logo


Sign up to stay informed
Whether you're taking ENJAYMO or interested in learning more, sign up to receive additional information, resources, and helpful tools to support you on your journey with Cold Agglutinin Disease.
Tell us who you are*
Are you or a loved one currently taking ENJAYMO? *
First Name *
Last Name *
Email *
Phone Number *
Street Address *
Address Continued (optional)
City *
State *
ZIP Code *
By checking this box and providing my personal information, I authorize Sanofi and its affiliates and agents (such as third-party business partners) to use my information for the following purposes: (1) sending me information about Cold Agglutinin Disease (CAD) and Sanofi products, promotions, services, and research studies; (2) asking my opinion about such information and topics through market research and disease-related surveys and sharing the information I provide with one another to perform these activities; and (3) using my de-identified information in performing research education, business analytics, marketing studies and other commercial activities. Sanofi may also share such personal information with regulatory authorities, if required. I understand that my information will not be sold to any third party. I am eighteen (18) years or older and am a resident of the United States. I authorize Sanofi, and its affiliates and agents, to contact me by mail, e-mail, fax, and/or telephone, including calls and text messages made using an automatic telephone dialing system at the telephone number(s) provided to provide me with the information I requested and other related information, or other topics of interest. Text message rates may apply. I understand that I am not required to consent as a condition of purchasing any property, goods, or services from Sanofi and may opt out of continued receipt of such communications at any time. To learn more about how your personal information is used and the rights you may have regarding this personal information, or to opt out of further communications, please visit
ENJAYMO® is a prescription medicine used to treat the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).

It is not known if ENJAYMO is safe and effective in children.
Do not receive ENJAYMO if you are allergic to sutimlimab-jome or any of the ingredients in ENJAYMO.
ENJAYMO can cause serious side effects, including:
Serious Infections: ENJAYMO is a prescription medicine that affects your immune system. ENJAYMO can lower the ability of your immune system to fight infections. People who take ENJAYMO may have an increased risk of getting infections caused by certain kinds of bacteria such as Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. These infections may be serious or life-threatening. Some infections may quickly become life-threatening or cause death if not recognized and treated early.
You need to receive vaccinations against infections caused by certain kinds of bacteria at least 2 weeks before your first dose of ENJAYMO. You may need to have additional vaccinations during treatment.
If your healthcare provider decides that urgent treatment with ENJAYMO is needed, you should receive vaccinations as soon as possible.
Vaccinations may reduce the risk of these infections, but do not prevent all infections. Call your healthcare provider or get medical help right away if you get any new signs and symptoms of an infection, including:
severe headache with stiff neck or back
pain during urination or urinating more
often than usual
cough or difficulty breathing
flu-like symptoms
pain, redness, or swelling of the skin
Infusion-related reactions: Treatment with ENJAYMO may cause infusion-related reactions, including allergic reactions that may be serious or life-threatening. Your healthcare provider may slow down or stop your ENJAYMO infusion if you have an infusion-related reaction and will treat your symptoms if needed. Tell your healthcare provider right away if you develop symptoms during your ENJAYMO infusion that may mean you are having an infusion-related reaction, including:
shortness of breath
decrease in blood pressure
chest discomfort
rapid heartbeat
injection site reaction
itchy skin
Risk of autoimmune disease: ENJAYMO may increase your risk for developing an autoimmune disease such as systemic lupus erythematosus (SLE). Tell your healthcare provider and get medical help if you develop any symptoms of SLE, including:
joint pain or swelling
rash on the cheeks and nose
unexplained fever
If you have CAD and you stop receiving ENJAYMO, your healthcare provider should monitor you closely for the return of your symptoms after you stop ENJAYMO. Stopping ENJAYMO may cause the breakdown of your red blood cells due to CAD return. Symptoms or problems that can happen due to red blood cell breakdown include:
shortness of breath
rapid heart rate
blood in your urine or
dark urine
The most common side effects of ENJAYMO include:
increase in blood
urinary tract infection
respiratory tract
bacterial infection
swelling in lower legs
or hands
joint pain
runny nose
bluish color to
the lips and skin
feeling tired or weak
changes in color or
sensation in the fingers
and toes (Raynaud's
These are not all the possible side effects of ENJAYMO. Call your doctor for medical advice about side effects.
Before receiving ENJAYMO, tell your healthcare provider about all of your medical conditions, including if you:
have a fever or infection, including a history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
have an autoimmune disease such as systemic lupus erythematosus (SLE), also known as lupus.
are pregnant or plan to become pregnant. It is not known if ENJAYMO will harm your unborn baby.
are breastfeeding or plan to breastfeed. It is not known if ENJAYMO passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
Back to the top